Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990040/S037

TRUFILL n-BCA Liquid Embolic System

Cerenovus, Inc. · Decision date Oct 23, 2026

MEDTECHLEDGER EXPLANATIONP990040/S037

What did the FDA approve?

The FDA recorded an approval decision on 2026-10-23 for P990040/S037, a PMA supplement to the TRUFILL n-BCA Liquid Embolic System (Cerenovus, Inc.). The supplement is filed under the Normal 180 Day Track No User Fee category with the reason Postapproval Study Protocol. The device category is a tissue adhesive for embolization of brain arteriovenous malformations, with Neurology as the listed specialty and KGG as the product code.

The recorded scope is narrow: this action approves the protocol for the TRUFILL post-approval study, submitted to comply with conditions of approval in the order for P990040/S034. It is not a new approval of the whole system, and the source does not describe protocol contents, study endpoints, enrollment, timelines, or the specific conditions from S034. No FDA documents were included in the source record, so those details remain unknown here.

FDA approval order statement

Approval of the protocol for the TRUFILL post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P990040/S034.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Oct 23, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P990040/S037
Regulatory pathway
PMA supplement
Product code
KGG
Decision code
APPR
Decision date
Oct 23, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.

Product code
KGG
FDA device class
3

For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P990040 · Original PMA

    TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM

  2. P990040/S037 received

    Application receipt date recorded by FDA.

  3. P990040/S037 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P990040

Product / regulatory recordCompanyPathwayDecision dateSource
Cerenovus, Inc.PMA approvalSep 25, 2000FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Cerenovus, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6303 Waterford District Dr., Suite 315, Miami, FL, 33126

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records